U.S. Physical Therapy, Inc. (NYSE:USPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, August 29th. The firm currently has a $64.00 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 5.87% from the company’s current price.
According to Zacks, “U.S. Physical Therapy, Inc. operates outpatient physical and occupational therapy clinics which provide post-operative care and treatment for a variety of orthopedic-related disorders and sports-related injuries. “
Several other research firms have also recently weighed in on USPH. Jefferies Group LLC set a $65.00 price objective on U.S. Physical Therapy and gave the stock a “hold” rating in a research report on Friday, August 4th. Cantor Fitzgerald assumed coverage on U.S. Physical Therapy in a research report on Monday, July 24th. They set an “overweight” rating and a $72.00 price objective on the stock. BidaskClub cut U.S. Physical Therapy from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 16th. Finally, Barrington Research upgraded U.S. Physical Therapy from a “market perform” rating to an “outperform” rating and set a $68.00 price target on the stock in a research report on Monday, July 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $68.60.
U.S. Physical Therapy (USPH) opened at 60.45 on Tuesday. U.S. Physical Therapy has a 52-week low of $51.96 and a 52-week high of $78.00. The stock has a 50 day moving average of $60.14 and a 200-day moving average of $63.80. The company has a market capitalization of $760.52 million, a P/E ratio of 38.26 and a beta of 1.07.
U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.01). The firm had revenue of $104.25 million for the quarter, compared to the consensus estimate of $102.93 million. U.S. Physical Therapy had a return on equity of 12.91% and a net margin of 5.65%. On average, equities analysts forecast that U.S. Physical Therapy will post $2.13 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “U.S. Physical Therapy, Inc. (NYSE:USPH) Stock Rating Upgraded by Zacks Investment Research” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2017/09/17/u-s-physical-therapy-inc-usph-raised-to-buy-at-zacks-investment-research.html.
In other news, COO Glenn Mcdowell sold 2,598 shares of U.S. Physical Therapy stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $57.00, for a total transaction of $148,086.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Lawrance W. Mcafee sold 3,000 shares of U.S. Physical Therapy stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $62.04, for a total value of $186,120.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,266 shares of company stock worth $801,134. Company insiders own 3.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of USPH. BlackRock Inc. lifted its stake in shares of U.S. Physical Therapy by 166,319.0% in the first quarter. BlackRock Inc. now owns 1,554,353 shares of the company’s stock worth $101,501,000 after acquiring an additional 1,553,419 shares during the period. Aberdeen Asset Management PLC UK lifted its stake in shares of U.S. Physical Therapy by 13.4% in the second quarter. Aberdeen Asset Management PLC UK now owns 705,007 shares of the company’s stock worth $42,582,000 after acquiring an additional 83,253 shares during the period. Renaissance Technologies LLC lifted its stake in shares of U.S. Physical Therapy by 10.4% in the second quarter. Renaissance Technologies LLC now owns 668,074 shares of the company’s stock worth $40,352,000 after acquiring an additional 63,074 shares during the period. Vanguard Group Inc. lifted its stake in shares of U.S. Physical Therapy by 6.5% in the first quarter. Vanguard Group Inc. now owns 641,533 shares of the company’s stock worth $41,892,000 after acquiring an additional 39,290 shares during the period. Finally, Bridge City Capital LLC acquired a new position in shares of U.S. Physical Therapy in the second quarter worth approximately $1,760,000. 95.50% of the stock is currently owned by institutional investors.
U.S. Physical Therapy Company Profile
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for U.S. Physical Therapy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.